Research - The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted on Tuesday to approve Regeneron (REGN) and Sanofi’s (SNY) cholesterol-lowering antibody, Praluent (alirocumab) – but with some caveats.
Premium: Read NowResearch - Shares of Sage Therapeutics (SAGE) climbed higher on Tuesday with the first glimpse at SAGE-547’s potential in post-partum depression. And with it went Marinus Pharmaceuticals … Continue Reading
Read NowResearch - QLT Inc. (QLTI) finally made the move we had been waiting for – although it's perhaps not the move we had been hoping for.
Premium: Read NowResearch - Updates on our Affimed (AFMD), Innate Pharma (IPH), and Oncothyreon (ONTY) coverage coming away from ASCO 2015.
Premium: Read NowResearch - The first of two phase 2 trials testing GlobeImmune’s (GBIM) GS-4774, an immunotherapy directed towards Hepatitis B and partnered with Gilead Sciences (GILD), has failed. The stock … Continue Reading
Read NowResearch - It’s been almost 30 years since the U.S. FDA approved the first statin to lower cholesterol, and the class remains the go-to therapy for treating hypercholesterolemia.
Premium: Read NowResearch - Following meetings with the U.S. FDA and Europe’s EMA, bluebird bio (BLUE) has clarity on the regulatory path for LentiGlobin BB305 in beta-thalassemia major. For … Continue Reading
Premium: Read Now
